Report Company Directory
- Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock by BusinessWire
- Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel by BusinessWire
- Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities by BusinessWire
- Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination by BusinessWire
- Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer by BusinessWire
- Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down by BusinessWire
- Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets by BusinessWire
- Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock by BusinessWire
- Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment by BusinessWire
- Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update by BusinessWire